Heng Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heng Zhao has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Haitang Yang
Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
8 shared publications Feng Yao
7 shared publicationsXufeng Pan
Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China (mainland)
6 shared publicationsYang Zhao
Department of Thoracic Surgery, Huadong Hospital Affiliated to FuDan University, Shanghai, China
6 shared publicationsHaiyong Gu
Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
4 shared publicationsJun Yang
Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
3 shared publications
Latest Publications
- Open Access
- 23 June 2021
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 8
Surgical Resection of Primary Tumors Provides Survival Benefits for Lung Cancer Patients With Unexpected Pleural Dissemination
Background: Surgery is not generally recommended for non-small cell lung cancer (NSCLC) patients with malignant pleural dissemination (PD). However, in some cases, PD is found unexpectedly during surgery. There is no consensus on whether surgical intervention can provide survival benefit for them. We investigated the role of surgery in NSCLC patients with unexpected PD by a cohort study.Methods: Clinical data of consecutive patients who intended to undergo radical surgery for NSCLC between January 2010 and December 2015 at Shanghai Chest Hospital and Huadong Hospital were collected from a lung cancer database. Patients diagnosed with unexpected malignant pleural nodules intraoperatively were enrolled in this retrospective study.Results: A total of 181 NSCLC patients were diagnosed with unexpected malignant PD intraoperatively and confirmed with postoperatively histological examinations. Out of these, 80 (44.2%) patients received pleural nodule biopsies alone, and 101 (55.8%) received primary tumor resection (47 with sublobar resection and 54 with lobectomy). The median progression-free survival and overall survival for all patients were 13 and 41 months respectively. Patients in the resection group had significantly better progression-free survival (19.0 vs. 10.0 months, P < 0.0001) and overall survival (48.0 vs. 33.0 months, P < 0.0001) than patients in the biopsy group. In the resection group, there was no statistical difference between patients with sublobar resection and lobectomy (P = 0.34). Univariate and multivariate analyses identified primary tumor resection, targeted adjuvant therapy, and tumor size (≤ 3 cm) as independent prognostic factors.Conclusions: NSCLC patients with unexpected intraoperative PD potentially benefited from surgical resection of the primary tumor and multidisciplinary targeted therapy, particularly when tumor size did not exceed 3 cm. Our data demonstrated that the resection type was not associated with survival differences, which remains to be defined with a larger sample size.
- 23 June 2021
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 8
Open AccessSurgical Resection of Primary Tumors Provides Survival Benefits for Lung Cancer Patients With Unexpected Pleural Dissemination
Background: Surgery is not generally recommended for non-small cell lung cancer (NSCLC) patients with malignant pleural dissemination (PD). However, in some cases, PD is found unexpectedly during surgery. There is no consensus on whether surgical intervention can provide survival benefit for them. We investigated the role of surgery in NSCLC patients with unexpected PD by a cohort study.Methods: Clinical data of consecutive patients who intended to undergo radical surgery for NSCLC between January 2010 and December 2015 at Shanghai Chest Hospital and Huadong Hospital were collected from a lung cancer database. Patients diagnosed with unexpected malignant pleural nodules intraoperatively were enrolled in this retrospective study.Results: A total of 181 NSCLC patients were diagnosed with unexpected malignant PD intraoperatively and confirmed with postoperatively histological examinations. Out of these, 80 (44.2%) patients received pleural nodule biopsies alone, and 101 (55.8%) received primary tumor resection (47 with sublobar resection and 54 with lobectomy). The median progression-free survival and overall survival for all patients were 13 and 41 months respectively. Patients in the resection group had significantly better progression-free survival (19.0 vs. 10.0 months, P < 0.0001) and overall survival (48.0 vs. 33.0 months, P < 0.0001) than patients in the biopsy group. In the resection group, there was no statistical difference between patients with sublobar resection and lobectomy (P = 0.34). Univariate and multivariate analyses identified primary tumor resection, targeted adjuvant therapy, and tumor size (≤ 3 cm) as independent prognostic factors.Conclusions: NSCLC patients with unexpected intraoperative PD potentially benefited from surgical resection of the primary tumor and multidisciplinary targeted therapy, particularly when tumor size did not exceed 3 cm. Our data demonstrated that the resection type was not associated with survival differences, which remains to be defined with a larger sample size.
- 27 November 2019
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 25, 9003-9011
Cavity Formation is a Prognostic Indicator for Pathologic Stage I Invasive Lung Adenocarcinoma of ≥3 cm in Size
BACKGROUND:We investigated the correlation between cavity formation, prognosis, and tumor stage for pathologic stage I invasive lung adenocarcinomas (IADCs) ≤3 cm in size. MATERIAL AND METHODS:2106 candidates with pathologic stage I IADC were ident...
- 27 November 2019
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 25, 9003-9011
Cavity Formation is a Prognostic Indicator for Pathologic Stage I Invasive Lung Adenocarcinoma of ≥3 cm in Size
BACKGROUND:We investigated the correlation between cavity formation, prognosis, and tumor stage for pathologic stage I invasive lung adenocarcinomas (IADCs) ≤3 cm in size. MATERIAL AND METHODS:2106 candidates with pathologic stage I IADC were ident...
- 1 September 2019
- Published by AME Publishing Company in Shanghai Chest
- Vol. 3, AB007
AB007. Modalities of tracheal resection and reconstruction-the Shanghai Chest Hospital experience
Background: The trachea surgery is generally performed due to stenosis, traumatic injury, foreign body and tumors with higher mortality and morbidity rates. Airway difficulties, hypoxia, stridor, cough, hemoptysis are common conditions in these patients. Methods: We analyzed the medical records of trachea surgery patients treated at Shanghai Chest Hospital from 1961 to February 2019. Surgical treatment of various tracheal diseases was conducted in 933 cases, including 565 males and 368 females with mean age of 41 (range, 3–76) years. The number of tracheal annular resection and anastomosis is 592, other surgery procedures include 98 carina resection and reconstruction, 53 open window operation, 60 sleeve pneumonectomy, 30 laryngectomy and laryngotracheal reconstruction, 35 carina reconstruction, 28 cardiopulmonary bypass assisted tracheal resection, and 37 other cases in this group. For upper tracheal lesion (cross neck and low collar), the classic incision is selected at 1cm above the clavicle head, and the length depends on the required exposure range above. For midtracheal lesion, transverse cervical incision combined with superior mediastinal incision (t-type incision) is conducted. The sternal incision is just above the sternal angle; total sternotomy is generally unnecessary and does not contribute to surgical field exposure. For lower trachea and carina lesions, right posterolateral incision (s-shaped incision, cut the 4th or 5th rib) provide good exposure (including left main branch). Trachea surgery in complex high-risk situations, minimally invasive cardiopulmonary bypass (a-v) and extracorporeal membrane oxygenation (ECMO) technical assistance (v-v) can provide the opportunity to operate. The extracorporeal circulation was stopped after tracheal resection and intraoperative intubation. The in vitro time was about 15 min. Thoracoscopic thoracic tracheal surgery and non-endotracheal intubation of the cervical trachea is also conducted. Results: Three hundred and forty-five non-neoplastic cases includes 15 congenital trachea malformation, 171 traumatic stenosis, 77 iatrogenic stenosis, 75 trachea fistula and 7 tracheal tuberculosis. Of the 515 malignant tumors, 467 were primary and 48 were secondary malignant tumors, includes 198 adenoid cystic carcinoma, 167 trachea squamous cell carcinoma, 37 adenocarcinoma, 10 carcinoid, 12 small cell carcinoma, 6 adenosquamous carcinoma, 1 low-differentiated carcinoma, 1 pale cell carcinoma, 41 thyroid cancer affects the trachea, 24 mucoepidermoid carcinoma, 6 bronchitis fibroblastoma, 7 esophageal cancer affects the trachea, 2 trachea lymphoma, 1 large cell neuroendocrine carcinoma, 2 peripheral lymphoepithelioma-like carcinoma. The 55 benign tumors include 12 leiomyoma, 6 fibroids, 4 angiomas, 3 hamartoma, 3 cyst, 14 peripheral schwannoma, 3 plasma cell tumors, 1 basal lipoma, 4 fibrohistiocytoma and 5 chondroma. No intraoperative death occurred in 933 cases and 3 cases died during perioperative period. Two cases of allogeneic tracheal transplantation, one case was reexcised 2 weeks after surgery due to graft softening. One patient survived 6.5 years after surgery, but died of metastasis due to tumor recurrence. Postoperative complications include 22 postoperative anastomotic opening, 25 recurrent laryngeal nerve injury, 30 anastomotic restenosis. Conclusions: Tracheal resection and reconstruction in the Shanghai Chest Hospital experience provide safe and useful methods for trachea patients. For complex high-risk trachea surgery, minimally invasive cardiopulmonary bypass and ECMO are useful.
- 1 September 2019
- Published by AME Publishing Company in Shanghai Chest
- Vol. 3, AB007
AB007. Modalities of tracheal resection and reconstruction-the Shanghai Chest Hospital experience
Background: The trachea surgery is generally performed due to stenosis, traumatic injury, foreign body and tumors with higher mortality and morbidity rates. Airway difficulties, hypoxia, stridor, cough, hemoptysis are common conditions in these patients. Methods: We analyzed the medical records of trachea surgery patients treated at Shanghai Chest Hospital from 1961 to February 2019. Surgical treatment of various tracheal diseases was conducted in 933 cases, including 565 males and 368 females with mean age of 41 (range, 3–76) years. The number of tracheal annular resection and anastomosis is 592, other surgery procedures include 98 carina resection and reconstruction, 53 open window operation, 60 sleeve pneumonectomy, 30 laryngectomy and laryngotracheal reconstruction, 35 carina reconstruction, 28 cardiopulmonary bypass assisted tracheal resection, and 37 other cases in this group. For upper tracheal lesion (cross neck and low collar), the classic incision is selected at 1cm above the clavicle head, and the length depends on the required exposure range above. For midtracheal lesion, transverse cervical incision combined with superior mediastinal incision (t-type incision) is conducted. The sternal incision is just above the sternal angle; total sternotomy is generally unnecessary and does not contribute to surgical field exposure. For lower trachea and carina lesions, right posterolateral incision (s-shaped incision, cut the 4th or 5th rib) provide good exposure (including left main branch). Trachea surgery in complex high-risk situations, minimally invasive cardiopulmonary bypass (a-v) and extracorporeal membrane oxygenation (ECMO) technical assistance (v-v) can provide the opportunity to operate. The extracorporeal circulation was stopped after tracheal resection and intraoperative intubation. The in vitro time was about 15 min. Thoracoscopic thoracic tracheal surgery and non-endotracheal intubation of the cervical trachea is also conducted. Results: Three hundred and forty-five non-neoplastic cases includes 15 congenital trachea malformation, 171 traumatic stenosis, 77 iatrogenic stenosis, 75 trachea fistula and 7 tracheal tuberculosis. Of the 515 malignant tumors, 467 were primary and 48 were secondary malignant tumors, includes 198 adenoid cystic carcinoma, 167 trachea squamous cell carcinoma, 37 adenocarcinoma, 10 carcinoid, 12 small cell carcinoma, 6 adenosquamous carcinoma, 1 low-differentiated carcinoma, 1 pale cell carcinoma, 41 thyroid cancer affects the trachea, 24 mucoepidermoid carcinoma, 6 bronchitis fibroblastoma, 7 esophageal cancer affects the trachea, 2 trachea lymphoma, 1 large cell neuroendocrine carcinoma, 2 peripheral lymphoepithelioma-like carcinoma. The 55 benign tumors include 12 leiomyoma, 6 fibroids, 4 angiomas, 3 hamartoma, 3 cyst, 14 peripheral schwannoma, 3 plasma cell tumors, 1 basal lipoma, 4 fibrohistiocytoma and 5 chondroma. No intraoperative death occurred in 933 cases and 3 cases died during perioperative period. Two cases of allogeneic tracheal transplantation, one case was reexcised 2 weeks after surgery due to graft softening. One patient survived 6.5 years after surgery, but died of metastasis due to tumor recurrence. Postoperative complications include 22 postoperative anastomotic opening, 25 recurrent laryngeal nerve injury, 30 anastomotic restenosis. Conclusions: Tracheal resection and reconstruction in the Shanghai Chest Hospital experience provide safe and useful methods for trachea patients. For complex high-risk trachea surgery, minimally invasive cardiopulmonary bypass and ECMO are useful.
- 1 July 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (7) , 4637-4642
Application of ex vivo lung perfusion (EVLP) in lung transplantation
Lung transplantation was the ultimate method to treat the end-stage benign lung diseases. Although the lung transplantation has been increasing quickly in the past 30 years, the shortage of donor lung still limited its development. Ex vivo lung perfusion (EVLP) was a promising technique that could provide the platform to preserve, evaluate and repair the donor lung graft. In this article, we give a general review of the development of EVLP, its clinical application and the animal model. With the increasing experience of clinical EVLP, some pre-identified unsuitable donor lungs have been re-evaluated and accepted for transplantation. EVLP have now been considered to be an effective way to expand the donor pool.
- 1 July 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (7) , 4637-4642
Application of ex vivo lung perfusion (EVLP) in lung transplantation
Lung transplantation was the ultimate method to treat the end-stage benign lung diseases. Although the lung transplantation has been increasing quickly in the past 30 years, the shortage of donor lung still limited its development. Ex vivo lung perfusion (EVLP) was a promising technique that could provide the platform to preserve, evaluate and repair the donor lung graft. In this article, we give a general review of the development of EVLP, its clinical application and the animal model. With the increasing experience of clinical EVLP, some pre-identified unsuitable donor lungs have been re-evaluated and accepted for transplantation. EVLP have now been considered to be an effective way to expand the donor pool.
- 1 July 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (7) , 4632-4636
Pulmonary retransplantation
Lung retransplantation has developed quickly these years with the increasing number of primary lung transplantation. But the operative risk and survival of lung retransplantation was inferior to primary lung transplantation. The bronchiolitis obliterans syndrome (BOS), the early graft failure and the irreversible airway complications are the main causes for lung retransplantation. In this review, we give a general view of the history of lung retransplantation. And we reviewed the factor related to the prognosis of lung retransplantation according to the previous publications. There have been four lung retransplantation in Shanghai Chest Hospital till now. We shared our preliminary experience here.
- 1 July 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (7) , 4632-4636
Pulmonary retransplantation
Lung retransplantation has developed quickly these years with the increasing number of primary lung transplantation. But the operative risk and survival of lung retransplantation was inferior to primary lung transplantation. The bronchiolitis obliterans syndrome (BOS), the early graft failure and the irreversible airway complications are the main causes for lung retransplantation. In this review, we give a general view of the history of lung retransplantation. And we reviewed the factor related to the prognosis of lung retransplantation according to the previous publications. There have been four lung retransplantation in Shanghai Chest Hospital till now. We shared our preliminary experience here.
- 1 April 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (4) , 2231-2239
Prognosis of limited resection versus lobectomy in elderly patients with invasive lung adenocarcinoma with tumor size less than or equal to 2 cm
Background: This study aimed to evaluate the prognostic difference between limited resection and lobectomy among elderly patients with small size lung adenocarcinoma. Methods: A total of 666 patients >65 years old with stage I lung adenocarcinoma and tumor size ≤2 cm were included. The patient survival was evaluated by disease-free survival (DFS) and overall survival (OS). Results: No DFS or OS advantage was found between the lobectomy and wedge resection groups when tumor sizes were ≤1 cm (DFS, P=0.112; OS, P=0.294). The wedge resection group had a significantly worse OS (P=0.041) than that in the lobectomy group when tumor sizes were >1 cm and ≤2 cm. Conclusions: We conclude that wedge resection may be a reasonable surgical choice for elderly patients with tumor sizes ≤1 cm.
- 1 April 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (4) , 2231-2239
Prognosis of limited resection versus lobectomy in elderly patients with invasive lung adenocarcinoma with tumor size less than or equal to 2 cm
Background: This study aimed to evaluate the prognostic difference between limited resection and lobectomy among elderly patients with small size lung adenocarcinoma. Methods: A total of 666 patients >65 years old with stage I lung adenocarcinoma and tumor size ≤2 cm were included. The patient survival was evaluated by disease-free survival (DFS) and overall survival (OS). Results: No DFS or OS advantage was found between the lobectomy and wedge resection groups when tumor sizes were ≤1 cm (DFS, P=0.112; OS, P=0.294). The wedge resection group had a significantly worse OS (P=0.041) than that in the lobectomy group when tumor sizes were >1 cm and ≤2 cm. Conclusions: We conclude that wedge resection may be a reasonable surgical choice for elderly patients with tumor sizes ≤1 cm.
- Open Access
- 14 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (49) , 86917-86923
S100A14 rs11548103 G>A polymorphism is associated with a decreased risk of esophageal cancer in a Chinese population
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Yang Zhao1, *, Feng Yao1, *, Weifeng Tang2, Haiyong Gu1 and Heng Zhao1 1Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China 2Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China *Joint first author Correspondence to: Haiyong Gu, email: haiyong_gu@hotmail.com Heng Zhao, email: h_zhao28@163.com Keywords: S100A14, polymorphisms, esophageal cancer, molecular epidemiology Received: December 19, 2016 Accepted: July 30, 2017 Published: September 14, 2017 ABSTRACT Objective: In China in 2009, esophageal cancer was the fifth most commonly diagnosed malignancy and the fourth leading cause of malignancy-related death. Accumulating evidence indicates that genetic factors might play an important role in esophageal squamous cell carcinoma (ESCC) carcinogenesis. Materials and Methods: In total, we recruited 629 ESCC patients and 686 controls. Genetic variations in the S100A14, MLH1, SMAD7 and CCL22/MDC genes were measured using the ligation detection reaction method. Results: When the S100A14 rs11548103 GG genotype was considered as the reference group, the GA genotype associated with decreased risk of ESCC (GA vs. GG: adjusted OR = 0.73, 95% CI = 0.57–0.93, p = 0.009). In the dominant model, GA/AA variants were associated with a significantly decreased risk of ESCC compared with the GG genotype (GA/AA vs. GG: adjusted OR = 0.76, 95% CI = 0.61–0.95, p = 0.018). Logistic regression analyses showed that the MLH1 rs1800734 C>T, SMAD7 rs12953717 C>T and CCL22/MDC rs4359426C>A polymorphisms were not associated with the risk of ESCC in any of the models tested. Conclusions: Our findings indicated that, in a Chinese population, rs11548103 might contribute to a decreased risk of ESCC. Further studies are need to confirm these data with results from a lager cohort and different ethnic origins.
- 14 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (49) , 86917-86923
Open AccessS100A14 rs11548103 G>A polymorphism is associated with a decreased risk of esophageal cancer in a Chinese population
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Yang Zhao1, *, Feng Yao1, *, Weifeng Tang2, Haiyong Gu1 and Heng Zhao1 1Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China 2Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China *Joint first author Correspondence to: Haiyong Gu, email: haiyong_gu@hotmail.com Heng Zhao, email: h_zhao28@163.com Keywords: S100A14, polymorphisms, esophageal cancer, molecular epidemiology Received: December 19, 2016 Accepted: July 30, 2017 Published: September 14, 2017 ABSTRACT Objective: In China in 2009, esophageal cancer was the fifth most commonly diagnosed malignancy and the fourth leading cause of malignancy-related death. Accumulating evidence indicates that genetic factors might play an important role in esophageal squamous cell carcinoma (ESCC) carcinogenesis. Materials and Methods: In total, we recruited 629 ESCC patients and 686 controls. Genetic variations in the S100A14, MLH1, SMAD7 and CCL22/MDC genes were measured using the ligation detection reaction method. Results: When the S100A14 rs11548103 GG genotype was considered as the reference group, the GA genotype associated with decreased risk of ESCC (GA vs. GG: adjusted OR = 0.73, 95% CI = 0.57–0.93, p = 0.009). In the dominant model, GA/AA variants were associated with a significantly decreased risk of ESCC compared with the GG genotype (GA/AA vs. GG: adjusted OR = 0.76, 95% CI = 0.61–0.95, p = 0.018). Logistic regression analyses showed that the MLH1 rs1800734 C>T, SMAD7 rs12953717 C>T and CCL22/MDC rs4359426C>A polymorphisms were not associated with the risk of ESCC in any of the models tested. Conclusions: Our findings indicated that, in a Chinese population, rs11548103 might contribute to a decreased risk of ESCC. Further studies are need to confirm these data with results from a lager cohort and different ethnic origins.
- Open Access
- 22 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (39) , 66576-66583
Visceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size ≤ 3cm
Visceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size ≤ 3cm
- 22 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (39) , 66576-66583
Open AccessVisceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size ≤ 3cm
Visceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size ≤ 3cm
- Open Access
- 1 January 2017
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 239-245
Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection
Purpose: The therapeutic efficacy of targeted therapy for adenosquamous carcinoma (ASC) of the lung remains unclear and the role of epidermal growth factor receptor (EGFR) testing in patients with ASC also remains controversial. We aimed to analyze the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in ASC. Methods: Clinical records of patients with ASC who received treatment with EGFR-TKIs between January 2006 and December 2014 at two institutions were retrospectively reviewed. Results: A total of 27 EGFR mutation-positive patients with ASC who received TKI therapy were enrolled in this study. EGFR mutations included a deletion in exon 19 in 15 cases and a point mutation at codon 858 (L858R) in exon 21 in 12 cases. Among the 27 ASC patients who received treatment with EGFR-TKIs, nine had a partial response and 11 achieved stable disease, accounting for a disease control rate of 74.1% (20/27). The median postoperative overall survival (OS) of the EGFR-mutant patients who received TKI therapy was 39 months (95% confidence interval [CI]: 25.6–52.4). The median progression-free survival for EGFR mutation-positive patients was 15 months (95% CI: 12.9–17.1), and the median relapse OS was 19 months (95% CI: 0.9–37.1). In addition, the 3- and 5-year postoperative survival rate was 51.9% and 15.3%, respectively. Conclusion: ASC patients harboring EGFR mutations had a good response to TKI therapy. Routine EGFR testing for ASCs was recommended. Further studies on TKI therapy versus chemotherapy alone for EGFR-mutant ASCs are required.
- 1 January 2017
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 239-245
Open AccessClinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection
Purpose: The therapeutic efficacy of targeted therapy for adenosquamous carcinoma (ASC) of the lung remains unclear and the role of epidermal growth factor receptor (EGFR) testing in patients with ASC also remains controversial. We aimed to analyze the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in ASC. Methods: Clinical records of patients with ASC who received treatment with EGFR-TKIs between January 2006 and December 2014 at two institutions were retrospectively reviewed. Results: A total of 27 EGFR mutation-positive patients with ASC who received TKI therapy were enrolled in this study. EGFR mutations included a deletion in exon 19 in 15 cases and a point mutation at codon 858 (L858R) in exon 21 in 12 cases. Among the 27 ASC patients who received treatment with EGFR-TKIs, nine had a partial response and 11 achieved stable disease, accounting for a disease control rate of 74.1% (20/27). The median postoperative overall survival (OS) of the EGFR-mutant patients who received TKI therapy was 39 months (95% confidence interval [CI]: 25.6–52.4). The median progression-free survival for EGFR mutation-positive patients was 15 months (95% CI: 12.9–17.1), and the median relapse OS was 19 months (95% CI: 0.9–37.1). In addition, the 3- and 5-year postoperative survival rate was 51.9% and 15.3%, respectively. Conclusion: ASC patients harboring EGFR mutations had a good response to TKI therapy. Routine EGFR testing for ASCs was recommended. Further studies on TKI therapy versus chemotherapy alone for EGFR-mutant ASCs are required.
- Open Access
- 20 June 2016
- Vol. 19 (6) , 337-342
第八版国际肺癌TNM分期修订稿解读
目前临床使用的肺癌分期是国际抗癌联盟(Union for International Cancer Control, UICC)于2009年1月颁布的第七版TNM分期。近年来,随着肺癌诊断技术的提高以及个体化治疗、分子靶向治疗等精准治疗模式的改变,肺癌的生存率及预后也有了明显的提高,旧的分期标准已难以适应当前的快速发展的临床需求。因此国际肺癌研究学会(International Association for the Study of Lung Cancer, IASLC)2015年对肺癌分期系统进行了更新,其修订稿发表于《Journal of Thoracic Oncology》,新版分期计划于2017年1月正式颁布实施。新分期标准采纳了来自16个国家的35个数据库,包含了自1999年-2010年间新发病的94, 708例肺癌病例。新版分期的优势在于能够更好的显示患者的预后,对临床具有更高的指导价值。
- 20 June 2016
- Vol. 19 (6) , 337-342
Open Access第八版国际肺癌TNM分期修订稿解读
目前临床使用的肺癌分期是国际抗癌联盟(Union for International Cancer Control, UICC)于2009年1月颁布的第七版TNM分期。近年来,随着肺癌诊断技术的提高以及个体化治疗、分子靶向治疗等精准治疗模式的改变,肺癌的生存率及预后也有了明显的提高,旧的分期标准已难以适应当前的快速发展的临床需求。因此国际肺癌研究学会(International Association for the Study of Lung Cancer, IASLC)2015年对肺癌分期系统进行了更新,其修订稿发表于《Journal of Thoracic Oncology》,新版分期计划于2017年1月正式颁布实施。新分期标准采纳了来自16个国家的35个数据库,包含了自1999年-2010年间新发病的94, 708例肺癌病例。新版分期的优势在于能够更好的显示患者的预后,对临床具有更高的指导价值。